CATCo Regulatory News (CAT)

4 Feb 2005 14:30

Cambridge Antibody Tech Group PLC04 February 2005 For further information contact: Weber Shandwick Square Mile (Europe)Cambridge Antibody Technology Tel: +44 (0) 20 7067 0700Tel: +44 (0) 1223 471 471 Kevin SmithPeter Chambre, Chief Executive Officer Yvonne AlexanderJohn Aston, Chief Financial Officer BMC Communications/The Trout Group (USA)Rowena Gardner, Director of Corporate Tel: +1 212 477 9007Communications Brad Miles, ext 17 (media) Brandon Lewis, ext 15 (investors) CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC REPORTS OUTCOME OF 2005 ANNUAL GENERAL MEETING Cambridge, UK...Cambridge Antibody Technology (LSE: CAT, NASDAQ: CATG) reportsthat at its Annual General Meeting, held at 12:30 GMT on Friday 4 February 2005,all resolutions were duly passed. -ENDS- Notes to EditorsCambridge Antibody Technology (CAT): • CAT is a biopharmaceutical company using its proprietary technologies and capabilities in human monoclonal antibodies for drug discovery and drug development. Based near Cambridge, England, CAT currently employs around 280 people • CAT is a leader in the discovery and development of human therapeutic antibodies and has an advanced proprietary technology for rapidly isolating human monoclonal antibodies using phage display and ribosome display systems. CAT has extensive phage antibody libraries, currently incorporating more than 100 billion distinct antibodies. These libraries form the basis for the Company's strategy to develop a portfolio of antibody-based drugs. • Four CAT human therapeutic antibody products are now at various stages of clinical development, with one further product candidate in pre-clinical development. • HUMIRA, the leading CAT-derived antibody, isolated and optimised in collaboration with Abbott, has been approved for marketing as a treatment for rheumatoid arthritis in 51 countries. • Six further licensed CAT-derived human therapeutic antibodies are in clinical development by licensees, with four further licensed product candidates in pre-clinical development. • CAT has alliances with a number of pharmaceutical and biotechnology companies to discover, develop and commercialise human monoclonal antibody-based products. • On 22 November 2004, CAT announced a major strategic alliance with AstraZeneca to discover and develop human antibody therapeutics in inflammatory disorders. • CAT has a broad collaboration with Genzyme for the development and commercialisation of antibodies directed against TGF, a family of proteins associated with fibrosis and scarring. This collaboration has so far given rise to one antibody product candidate at clinical development stage, and one at pre-clinical development stage. • CAT has also licensed its proprietary technologies to several companies. CAT's licensees include: Abbott, Amgen, Chugai, Genzyme, Human Genome Sciences, Merck & Co, Pfizer and Wyeth Research. • CAT is listed on the London Stock Exchange and on NASDAQ. CAT raised £41m in its IPO in March 1997 and £93m in a secondary offering in March 2000. Application of the Safe Harbor of the Private Securities Litigation Reform Actof 1995: This press release contains statements about Cambridge AntibodyTechnology Group plc ("CAT") that are forward looking statements. All statementsother than statements of historical facts included in this press release may beforward looking statements within the meaning of Section 21E of the SecuritiesExchange Act of 1934. These forward looking statements are based on numerousassumptions regarding the company's present and future business strategies andthe environment in which the company will operate in the future. Certain factorsthat could cause the company's actual results, performance or achievements todiffer materially from those in the forward looking statements include: marketconditions, CAT's ability to enter into and maintain collaborative arrangements,success of product candidates in clinical trials, regulatory developments andcompetition. We caution investors not to place undue reliance on the forwardlooking statements contained in this press release. These statements speak onlyas of the date of this press release, and we undertake no obligation to updateor revise the statements. This information is provided by RNS The company news service from the London Stock Exchange